Viability of autoantibody-targets: How to tackle pathogenetic heterogeneity as an obstacle for treatment of multiple sclerosis. Mayer M C, Hohlfeld R, Meinl E J Neurol Sci. 2012 May 28. PMID: 22647585. Abstract CommentRecommendBookmarkWatch